2016 New Antibacterial Discovery and Development Gordon Research Conference and Gordon Research Seminar

 描述(申请人提供)：2016年戈登新抗菌药物发现和开发研究会议和伴随的戈登研究研讨会将把抗菌药物发现和开发方面经验丰富的领导者与年轻的研究人员和抗生素研究领域的新手聚集在一起，以使下一代安全有效的药物成为可能。讨论负责人和演讲者来自学术界、工业界和政府机构，以强调围绕目标发现和验证、命中识别推动创新所需的才华和领导力的广度 和化学优化，以及临床试验的设计和实施。以前的会议已经确定了抗生素耐药性的问题，过去20年来抗生素发现和开发所面临的挑战，以及临床开发新途径的必要性。这些会议成功地在一个竞争激烈的科学舞台上创造了一个创意产生和合作的社区。本次会议将通过探索1)针对最难治疗的生物体获得有效和安全的抗菌药物的新策略，2)诊断感染的新方法，目标是扩大临床开发机会并指导宝贵的新抗菌药物在临床上的适当使用，以及3)从最近的临床项目中学习新的和确定的目标，可能被转化为下一代抗菌药物，从而为这些基础奠定基础。在过去的几年里，生物技术和制药行业发生了许多战略和组织上的变化，学术和政府研究机构的重点也从早期的基础科学转向了转化性研究。由于环境的不断变化，对于培养一群致力于创新和精心计算的冒险精神的知识分子来说，现在是前所未有的关键时刻。这 GRC/GRS将促进批判性思维，围绕数据收集和解释进行强有力的讨论，并从彼此的挑战和成功中学习。最重要的是，GRC/GRS会议将为那些致力于人类医学最困难和最重要领域之一的科学家提供一个社区和支持网络。

 DESCRIPTION (provided by the applicant): The 2016 Gordon Research Conference on New Antibacterial Discovery and Development and the companion Gordon Research Seminar will bring highly experienced leaders in antibacterial drug discovery and development together with young investigators and those new to the field of antibiotics research in order to enable the next generation of safe and effective drugs. Discussion leaders and speakers are chosen from academia, industry, and government agencies to emphasize the breadth of talent and leadership necessary to drive innovation around target discovery and validation, hit identification and chemical optimization, and clinical trial design and execution. Previous meetings have defined the problem of antibiotic resistance, the challenges in antibiotic discovery and development faced over the past two decades, and the need for new pathways for clinical development. Those meetings have successfully created a community of idea generation and collaboration in what is otherwise a highly competitive scientific arena. This meeting will build o those foundations by exploring 1) novel strategies for achieving potent and safe antibacterial drugs against the most difficult-to- treat organisms, 2) new approaches for diagnosing infections with the goal of broadening the opportunities for clinical development as well as guiding the appropriate use of precious new antibacterial drugs in the clinic, and 3) learnings from recent clinical programs with new and established targets which may be translatable to the next generation of antibacterial drugs. Many strategic and organizational changes have taken place in the biotech and pharmaceutical industry over the last few years as well as a shift in emphasis at academic and government research facilities from early basic science to translational research. Because of the ever-changing environment, there has never been a more critical time for fostering a community of intellectuals dedicated to innovation and calculated risk-taking. This GRC/GRS will enable critical thinking, robust discussions around data gathering and interpretation, and learning from each other's challenges and successes. Most importantly the GRC/GRS meeting will provide a community and support network for scientists who have dedicated their careers to one of the most difficult and essential areas of human medicine.